Document is current
Any future updates will be listed below
-
Authors
Fujisaka, Shiho https://orcid.org/0000-0003-0554-9003
Watanabe, Yoshiyuki
Toume, Kazufumi
Morinaga, Yoshitomo
Nawaz, Allah
Kado, Tomonobu
Nishimura, Ayumi
Bilal, Muhammad
Aslam, Muhammad Rahil
Igarashi, Yoshiko
Nakagawa, Yoshimi
Tobe, Kazuyuki
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (20K08882)
Japan Society for the Promotion of Science (21K20896)
Japan Society for the Promotion of Science (22K16424)
Japan Agency for Medical Research and Development (JP18gm6010023h0001)
Japan Diabetes Foundation (0)
Lotte Foundation (0)
Yakult Bio-Science Foundation (0)
First Bank of Toyama Scholarship Foundation (0)
- License Information
-
More Information
Article History
Received: 5 December 2023
Accepted: 12 March 2024
First Online: 6 April 2024
Declarations
:
: KT received lecture fees from MSD K.K., Novo Nordisk Pharma Ltd., and Kowa Pharmaceutical Co. Ltd. and grants from Daiichi Sankyo Co. Ltd., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., MSD K.K., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Limited, Eli Lilly Japan K.K., Asahi Kasei Pharma Corporation, and the Mitsubishi Foundation.
: The animal care policies and experimental procedures were approved by the Animal Experiment Committee of the University of Toyama (date of approval: April 4th 2022, approval number: A2022MED-20). All animal experiments complied with the ARRIVE guidelines and were carried out in accordance with the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978<sup>)</sup>.
